BACKGROUND: Low serum albumin is common and associated with protein-energy wasting, inflammation, and poor outcomes in maintenance hemodialysis (MHD) patients. We hypothesized that in-center (in dialysis clinic) provision of high-protein oral nutrition supplements (ONS) tailored for MHD patients combined with anti-oxidants and anti-inflammatory ingredients with or without an anti-inflammatory appetite stimulator (pentoxifylline, PTX) is well tolerated and can improve serum albumin concentration. METHODS:Between January 2008 and June 2010, 84 adult hypoalbuminemic (albumin <4.0 g/dL) MHD outpatients were double-blindly randomized to receive 16 weeks of interventions including ONS, PTX, ONS with PTX, or placebos. Nutritional and inflammatory markers were compared between the four groups. RESULTS:Out of 84 subjects (mean ± SD; age, 59 ± 12 years; vintage, 34 ± 34 months), 32 % were Blacks, 54 % females, and 68 % diabetics. ONS, PTX, ONS plus PTX, and placebo were associated with an average change in serum albumin of +0.21 (P = 0.004), +0.14 (P = 0.008), +0.18 (P = 0.001), and +0.03 g/dL (P = 0.59), respectively. No related serious adverse events were observed. In a predetermined intention-to-treat regression analysis modeling post-trial serum albumin as a function of pre-trial albumin and the three different interventions (ref = placebo), only ONS without PTX was associated with a significant albumin rise (+0.17 ± 0.07 g/dL, P = 0.018). CONCLUSIONS: In this pilot-feasibility, 2 × 2 factorial, placebo-controlled trial, daily intake of a CKD-specific high-protein ONS with anti-inflammatory and anti-oxidative ingredients for up to 16 weeks was well tolerated and associated with slight but significant increase in serum albumin levels. Larger long-term controlled trials to examine hard outcomes are indicated.
RCT Entities:
BACKGROUND: Low serum albumin is common and associated with protein-energy wasting, inflammation, and poor outcomes in maintenance hemodialysis (MHD) patients. We hypothesized that in-center (in dialysis clinic) provision of high-protein oral nutrition supplements (ONS) tailored for MHD patients combined with anti-oxidants and anti-inflammatory ingredients with or without an anti-inflammatory appetite stimulator (pentoxifylline, PTX) is well tolerated and can improve serum albumin concentration. METHODS: Between January 2008 and June 2010, 84 adult hypoalbuminemic (albumin <4.0 g/dL) MHD outpatients were double-blindly randomized to receive 16 weeks of interventions including ONS, PTX, ONS with PTX, or placebos. Nutritional and inflammatory markers were compared between the four groups. RESULTS: Out of 84 subjects (mean ± SD; age, 59 ± 12 years; vintage, 34 ± 34 months), 32 % were Blacks, 54 % females, and 68 % diabetics. ONS, PTX, ONS plus PTX, and placebo were associated with an average change in serum albumin of +0.21 (P = 0.004), +0.14 (P = 0.008), +0.18 (P = 0.001), and +0.03 g/dL (P = 0.59), respectively. No related serious adverse events were observed. In a predetermined intention-to-treat regression analysis modeling post-trial serum albumin as a function of pre-trial albumin and the three different interventions (ref = placebo), only ONS without PTX was associated with a significant albumin rise (+0.17 ± 0.07 g/dL, P = 0.018). CONCLUSIONS: In this pilot-feasibility, 2 × 2 factorial, placebo-controlled trial, daily intake of a CKD-specific high-protein ONS with anti-inflammatory and anti-oxidative ingredients for up to 16 weeks was well tolerated and associated with slight but significant increase in serum albumin levels. Larger long-term controlled trials to examine hard outcomes are indicated.
Authors: J D Palombo; S J DeMichele; P J Boyce; E E Lydon; J W Liu; Y S Huang; R A Forse; J P Mizgerd; B R Bistrian Journal: Crit Care Med Date: 1999-09 Impact factor: 7.598
Authors: A Rashid Qureshi; Anders Alvestrand; José C Divino-Filho; Alberto Gutierrez; Olof Heimbürger; Bengt Lindholm; Jonas Bergström Journal: J Am Soc Nephrol Date: 2002-01 Impact factor: 10.121
Authors: Todd W Rice; Arthur P Wheeler; B Taylor Thompson; Bennett P deBoisblanc; Jay Steingrub; Peter Rock Journal: JAMA Date: 2011-10-05 Impact factor: 56.272
Authors: D B Cockram; M K Hensley; M Rodriguez; G Agarwal; A Wennberg; P Ruey; D Ashbach; L Hebert; R Kunau Journal: J Ren Nutr Date: 1998-01 Impact factor: 3.655
Authors: Connie M Rhee; Matthew Budoff; Gregory Brent; Amy S You; Peter Stenvinkel; Alejandra Novoa; Ferdinand Flores; Sajad Hamal; Christopher Dailing; April Kinninger; Tracy Nakata; Csaba P Kovesdy; Danh V Nguyen; Kamyar Kalantar-Zadeh Journal: Cardiorenal Med Date: 2022-05-12 Impact factor: 4.360
Authors: Kamyar Kalantar-Zadeh; Linda W Moore; Amanda R Tortorici; Jason A Chou; David E St-Jules; Arianna Aoun; Vanessa Rojas-Bautista; Annelle K Tschida; Connie M Rhee; Anuja A Shah; Susan Crowley; Joseph A Vassalotti; Csaba P Kovesdy Journal: BMC Nephrol Date: 2016-07-19 Impact factor: 2.388
Authors: Connie M Rhee; Amy S You; Tara Koontz Parsons; Amanda R Tortorici; Rachelle Bross; David E St-Jules; Jennie Jing; Martin L Lee; Debbie Benner; Csaba P Kovesdy; Rajnish Mehrotra; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: Nephrol Dial Transplant Date: 2017-07-01 Impact factor: 5.992
Authors: Jia Yee Mah; Suet Wan Choy; Matthew A Roberts; Anne Marie Desai; Melissa Corken; Stella M Gwini; Lawrence P McMahon Journal: Cochrane Database Syst Rev Date: 2020-05-11